Biocon arm gets Ontario listing for retinal drug; check details

The drug is available in vial and prefilled syringe formats, 2 mg/0.05 mL, for treating retinal diseases in Canada. Yesafili was the first biosimilar to Eylea approved by Health Canada.

The Ontario Drug Benefit (ODB) Formulary is the official list of prescription medicines covered under Ontario’s public insurance program. The listing took effect on August 29, 2025, making Yesafili accessible to eligible patients through public funding, the company said in an exchange filing.

Conditions such as wet AMD affect over 2 million Canadians and are among the leading causes of permanent vision loss worldwide, creating challenges for patients, caregivers and healthcare systems.

This follows the September 17 development, when Biocon Biologics secured USFDA approval for two denosumab biosimilars - Bosaya and Aukelso.

While Bosaya will be available in a 60 mg/mL injection for subcutaneous use in a single-dose prefilled syringe, Aukelso will be available as a 120 mg/1.7 mL (70 mg/mL) injection for subcutaneous use in a single-dose vial. Both are denosumab biosimilars of Prolia and Xgeva, respectively, Biocon said in a regulatory filing.

Biocon stock performance:

Shares of Biocon settled at 4.25% higher at ₹369.40 apiece on the National Stock Exchange (NSE) on Thursday. However, the announcement came after market hours.

In the last five trading sessions, shares of Biocon Limited gained 1.12%. On the other hand, the scrip also advanced 1.40% in the last month. The stock zoomed 9.83% in the six month period.

The stock touched its 52 week high of ₹406 on July 18, 2025 and its 52 week low of ₹291 on March 3, 2025. The company’s market capitalisation currently stands at ₹49,387.44 crore.

Biocon Q1 results:

In the latest quarterly earnings season, the company’s revenue for the quarter jumped 14.8% YoY to ₹3,941 crore as against ₹3,432 crore. On the other hand, the operational profit or EBITDA for the quarter stood at ₹748 crore, up by 20% YoY. Whereas the bottom line for the quarter stood at ₹89 crore as compared to ₹861 crore, which included higher other income.